SILK - Silk Road Medical Inc Stock Price, Fair Value and News

17.57USD-0.10 (-0.57%)Market Closed

Market Summary

USD17.57-0.10

Market Closed

-0.57%

SILK Stock Price

View Fullscreen

SILK RSI Chart

SILK Valuation

Market Cap

692.2M

Price/Earnings (Trailing)

-12.42

Price/Sales (Trailing)

3.91

Price/Free Cashflow

-20.65

SILK Price/Sales (Trailing)

SILK Profitability

Return on Equity

-36.88%

Return on Assets

-21.01%

Free Cashflow Yield

-4.84%

SILK Fundamentals

SILK Revenue

Revenue (TTM)

177.1M

Rev. Growth (Yr)

17.97%

Rev. Growth (Qtr)

6.38%

SILK Earnings

Earnings (TTM)

-55.7M

Earnings Growth (Yr)

-3.15%

Earnings Growth (Qtr)

-1.74%

Breaking Down SILK Revenue

Last 7 days

-0.2%

Last 30 days

-5.1%

Last 90 days

18.2%

Trailing 12 Months

-61.1%

How does SILK drawdown profile look like?

SILK Financial Health

Current Ratio

7.95

Debt/Equity

0.5

Debt/Cashflow

-0.42

SILK Investor Care

Shares Dilution (1Y)

1.85%

Diluted EPS (TTM)

-1.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	150.7M	162.9M	169.9M	177.1M
2022	107.4M	114.2M	126.8M	138.6M
2021	78.3M	89.7M	94.3M	101.5M
2020	69.5M	69.7M	72.7M	75.2M
2019	41.6M	48.8M	56.2M	63.4M
2018	19.3M	24.4M	29.5M	34.6M
2017	0	0	0	14.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Silk Road Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	klemz kevin m	sold	-42,871	17.169	-2,497	evp/chief legal officer/sec.
Mar 05, 2024	ruedy richard	sold	-65,242	17.169	-3,800	evpclin&reg.affairs&qa
Mar 05, 2024	buchanan lucas w.	sold	-169,578	17.169	-9,877	coo/cfo
Mar 05, 2024	ballinger kevin j.	bought	198,783	16.99	11,700	-
Mar 05, 2024	davis andrew s.	sold	-94,103	17.169	-5,481	chief commercial officer
Mar 05, 2024	jones marie l.	sold	-44,673	17.169	-2,602	vp, finance and cao
Mar 01, 2024	klemz kevin m	acquired	-	-	42,818	evp/chief legal officer/sec.
Mar 01, 2024	mckhann chas	acquired	-	-	110,313	chief executive officer
Mar 01, 2024	davis andrew s.	acquired	-	-	62,201	chief commercial officer
Mar 01, 2024	buchanan lucas w.	acquired	-	-	74,954	coo/cfo

Which funds bought or sold SILK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.35	-43,000	24,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-54,482	245,768	-%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	new	-	2,000	2,000	-%
Apr 18, 2024	WASATCH ADVISORS LP	added	12.36	33,668,100	83,351,300	0.44%
Apr 12, 2024	AdvisorNet Financial, Inc	reduced	-73.4	-31,692	20,885	-%
Apr 05, 2024	CWM, LLC	added	0.74	16,000	47,000	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	165	165	-%
Apr 03, 2024	Versant Capital Management, Inc	unchanged	-	399	1,209	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-330	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	1,293	28,245	30,958	-%

Are Funds Buying or Selling SILK?

Are funds buying SILK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SILK

No. of Funds

Unveiling Silk Road Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.43%	2,891,769	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 05, 2024	goldman sachs group inc	5.8%	2,277,063	SC 13G
Jan 26, 2024	blackrock inc.	7.7%	3,012,320	SC 13G/A
Oct 20, 2023	flynn james e	0.00%	0	SC 13G
Aug 10, 2023	alliancebernstein l.p.	0.1%	46,800	SC 13G/A
May 10, 2023	wasatch advisors lp	-	0	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	6.9%	2,616,795	SC 13G/A
Feb 13, 2023	capital world investors	7.8%	2,966,730	SC 13G/A
Feb 10, 2023	flynn james e	3.66%	1,396,640	SC 13G/A

Recent SEC filings of Silk Road Medical Inc

View All Filings

Date Filed	Form Type	Document
Mar 07, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Silk Road Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.4B	3.9B	-2.36%	-14.10%	52.63	6.06	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.48	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.58	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

Silk Road Medical Inc News

Latest updates

Silk Road Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.4%	47,270,000	44,435,000	45,298,000	40,131,000	40,070,500	37,374,000	33,173,000	28,021,000	28,265,000	24,701,000	26,456,000	22,053,000	21,133,000	20,067,000	15,094,000	18,933,000	18,634,000	17,026,000	14,928,000	12,766,000	11,470,000
Gross Profit	7.5%	34,802,000	32,385,000	32,294,000	27,605,000	29,091,500	28,066,000	24,161,000	19,444,000	21,031,500	18,625,000	19,858,000	16,515,000	15,916,000	14,579,000	9,758,000	13,683,000	13,913,000	12,856,000	11,231,000	9,427,000	7,803,000
Operating Expenses	6.8%	49,175,000	46,056,000	46,610,000	44,515,000	41,721,500	37,292,000	38,355,000	35,398,000	35,093,500	31,916,000	29,810,000	26,678,000	30,909,500	23,913,000	19,151,000	22,823,000	21,420,000	20,251,000	17,248,000	16,573,000	15,102,000
S&GA Expenses	8.6%	39,111,000	36,009,000	35,830,000	34,082,000	32,521,500	28,821,000	27,700,000	27,275,000	27,595,000	25,049,000	22,549,000	21,194,000	20,872,000	19,202,000	15,758,000	19,692,000	18,155,500	17,064,000	14,135,000	13,866,000	11,712,000
R&D Expenses	0.2%	10,064,000	10,047,000	10,780,000	10,433,000	9,200,000	8,471,000	10,655,000	8,123,000	7,498,500	6,867,000	7,261,000	5,484,000	10,037,500	4,711,000	3,393,000	3,131,000	3,264,500	3,187,000	3,113,000	2,707,000	3,390,000
EBITDA Margin	-	-	-	-	-	-	-	-0.41	-0.44	-0.47	-	-	-0.55	-0.56	-0.64	-0.67	-0.67	-0.74	-0.57	-0.66	-0.78	-
Interest Expenses	0.1%	1,734,000	1,732,000	1,712,000	1,693,000	1,732,000	1,714,000	1,031,000	621,000	634,000	633,000	628,000	623,000	791,000	1,215,000	1,203,000	1,202,000	1,216,500	1,176,000	1,207,000	1,352,000	1,296,000
EBT Margin	-	-	-	-	-	-	-	-0.44	-0.46	-0.49	-	-	-0.60	-0.63	-0.72	-0.75	-0.75	-0.83	-0.67	-0.77	-0.90	-
Net Income	-1.7%	-13,011,000	-12,788,000	-13,484,000	-16,460,000	-12,614,000	-10,319,000	-15,398,000	-16,679,000	-14,693,000	-13,885,000	-10,539,000	-10,694,000	-16,756,000	-10,315,000	-10,353,000	-9,941,000	-8,291,000	-8,007,000	-11,959,000	-24,158,000	-15,618,000
Net Income Margin	3.4%	-0.31	-0.33	-0.32	-0.36	-0.40	-0.45	-0.53	-0.52	-0.49	-0.55	-0.54	-0.61	-	-	-	-	-	-	-	-	-
Free Cashflow	-24.9%	-8,906,000	-7,131,000	-5,050,000	-12,434,000	-4,291,000	-5,115,000	-11,383,000	-16,797,000	-14,184,000	-7,627,000	-9,843,000	-12,039,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.7%	265	261	263	260	270	163	163	143	157	166	168	170	179	184	188	127	137	139	143	39.00	43.00
Current Assets	-0.1%	241	241	233	230	255	147	147	128	143	154	159	164	173	178	181	120	112	132	136	29.00	39.00
Cash Equivalents	-30.8%	20.00	29.00	28.00	50.00	55.00	51.00	88.00	94.00	110	106	102	95.00	70.00	63.00	74.00	28.00	39.00	113	119	16.00	25.00
Inventory	35.4%	30.00	22.00	19.00	17.00	19.00	20.00	18.00	18.00	18.00	16.00	13.00	12.00	10.00	11.00	12.00	12.00	10.00	9.00	9.00	8.00	6.00
Net PPE	-2.7%	8.00	8.00	9.00	9.00	9.00	10.00	10.00	10.00	8.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	6.0%	114	108	108	102	106	105	103	75.00	77.00	77.00	72.00	69.00	72.00	64.00	60.00	63.00	66.00	61.00	58.00	91.00	72.00
Current Liabilities	26.1%	30.00	24.00	24.00	21.00	24.00	24.00	21.00	29.00	26.00	21.00	17.00	16.00	20.00	15.00	12.00	14.00	17.00	12.00	9.00	11.00	11.00
Short Term Borrowings	-	-	-	-	-	-	-	-	10.00	4.00	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	0.3%	76.00	75.00	75.00	75.00	75.00	74.00	74.00	39.00	45.00	49.00	49.00	49.00	49.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	44.00
LT Debt, Non Current	0.3%	76.00	75.00	75.00	75.00	75.00	74.00	74.00	39.00	45.00	49.00	49.00	49.00	49.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	44.00
Shareholder's Equity	-1.3%	151	153	156	158	164	57.00	60.00	68.00	79.00	88.00	96.00	101	108	120	127	64.00	72.00	77.00	84.00	-	-
Retained Earnings	-3.4%	-399	-386	-373	-360	-343	-331	-320	-305	-288	-274	-260	-249	-238	-222	-211	-201	-191	-183	-175	-163	-139
Additional Paid-In Capital	2.0%	550	540	529	518	508	388	381	373	368	362	356	351	346	342	339	265	263	261	260	5.00	5.00
Shares Outstanding	0.7%	39.00	39.00	39.00	39.00	38.00	35.00	35.00	35.00	35.00	35.00	34.00	34.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,200	-	-	-	1,300	-	-	-	1,600	-	-	-	1,400	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-24.3%	-8,453	-6,798	-4,616	-12,147	-2,724	-4,726	-10,406	-14,725	-11,432	-6,495	-9,036	-11,972	-14,269	-4,423	-11,581	-11,795	-5,261	-6,346	-9,383	-8,620	-5,390
Share Based Compensation	-6.2%	9,609	10,247	10,199	8,838	7,545	6,339	6,161	4,978	3,984	3,686	3,409	3,533	2,273	2,006	1,654	1,293	954	924	837	262	226
Cashflow From Investing	-121.2%	-1,580	7,456	-19,158	6,106	-104,951	-32,895	-22,150	-2,072	14,250	7,968	14,193	36,233	12,898	-7,386	-14,797	-108	-69,619	-131	-89.00	-117	-102
Cashflow From Financing	711.5%	1,055	130	1,592	1,110	111,727	1,213	26,591	168	1,771	2,242	2,117	848	8,369	835	72,268	274	1,784	507	112,210	-744	-226

SILK Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statements of Operations and Comprehensive Loss [Abstract]
Revenue	$ 177,134	$ 138,638	$ 101,475
Cost of goods sold	50,048	37,876	25,446
Gross profit	127,086	100,762	76,029
Operating expenses:
Research and development	41,324	36,449	27,110
Selling, general and administrative	145,033	116,317	96,387
Total operating expenses	186,357	152,766	123,497
Loss from operations	(59,271)	(52,004)	(47,468)
Interest income	9,957	2,527	198
Interest expense	(6,871)	(5,098)	(2,518)
Loss on debt extinguishment		(245)
Other income (expense), net	442	(190)	(23)
Net loss	(55,743)	(55,010)	(49,811)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net	238	(166)	(39)
Other comprehensive income (loss)	238	(166)	(39)
Comprehensive loss	$ (55,505)	$ (55,176)	$ (49,850)
Net loss per share, basic	$ (1.44)	$ (1.54)	$ (1.44)
Net loss per share, diluted	$ (1.44)	$ (1.54)	$ (1.44)
Weighted average common shares used to compute net loss per share, basic	38,804,343	35,775,672	34,635,358
Weighted average common shares used to compute net loss per share, diluted	38,804,343	35,775,672	34,635,358

SILK Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 20,210,000	$ 55,358,000
Short-term investments	161,264,000	158,316,000
Accounts receivable, net of allowances of $26 and $3 at December 31, 2023 and December 31, 2022, respectively	23,573,000	18,007,000
Inventories	29,876,000	19,293,000
Prepaid expenses and other current assets	5,912,000	3,924,000
Total current assets	240,835,000	254,898,000
Long-term investments	9,456,000
Property and equipment, net	8,114,000	9,372,000
Restricted cash	0	155,000
Other non-current assets	6,904,000	5,260,000
Total assets	265,309,000	269,685,000
Current liabilities:
Accounts payable	5,676,000	2,523,000
Accrued liabilities	24,607,000	21,965,000
Total current liabilities	30,283,000	24,488,000
Long-term debt	75,626,000	74,596,000
Other liabilities	8,249,000	6,726,000
Total liabilities	114,158,000	105,810,000
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: none at December 31, 2023 and 2022
Common stock, $0.001 par value Shares authorized: 100,000,000 at December 31, 2023 and 2022 Shares issued and outstanding: 39,165,481 and 38,355,972 at December 31, 2023 and 2022, respectively	39,000	38,000
Additional paid-in capital	550,495,000	507,715,000
Accumulated other comprehensive income (loss)	72,000	(166,000)
Accumulated deficit	(399,455,000)	(343,712,000)
Total stockholders’ equity	151,151,000	163,875,000
Total liabilities and stockholders’ equity	$ 265,309,000	$ 269,685,000

About Silk Road Medical Inc

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure. Silk Road Medical, Inc. was incorporated in 2007 and is headquartered in Sunnyvale, California.

CEO	Ms. Erica J. Rogers
WEBSITE	https://silkroadmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	414

Silk Road Medical Inc Frequently Asked Questions

What is the ticker symbol for Silk Road Medical Inc? What does SILK stand for in stocks?

SILK is the stock ticker symbol of Silk Road Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silk Road Medical Inc (SILK)?

As of Tue Apr 23 2024, market cap of Silk Road Medical Inc is 692.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers. The fair value of Silk Road Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Silk Road Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SILK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Silk Road Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SILK is over valued or under valued. Whether Silk Road Medical Inc is cheap or expensive depends on the assumptions which impact Silk Road Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILK.

What is Silk Road Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, SILK's PE ratio (Price to Earnings) is -12.42 and Price to Sales (PS) ratio is 3.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILK PE ratio will change depending on the future growth rate expectations of investors.